Serum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndrome

Basit Öğe Kaydı
dc.authoridEngin-Ustun, Yaprak/0000-0002-1011-3848
dc.authorwosidUstun, Yaprak/KFQ-9767-2024
dc.authorwosidÜstün, Yusuf/AAC-2674-2020
dc.contributor.authorCakal, E.
dc.contributor.authorOzkaya, M.
dc.contributor.authorEngin-Ustun, Y.
dc.contributor.authorUstun, Y.
dc.date.accessioned2024-08-04T20:32:50Z
dc.date.available2024-08-04T20:32:50Z
dc.date.issued2011
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: Our aim was to investigate levels of lipocalin-2 and its relationship with metabolic factors in women with polycystic ovary syndrome (PCOS). Materials/Subjects and methods: In this cross-sectional study, two groups of women were studied: group 1 consisted of women with PCOS (no.=30), and group 2 consisted of control women with normal ovulatory function (no.=30). The circulating levels of free testosterone (T), DHEAS, glucose, insulin, triglycerides (TG), HDL, LDL and lipocalin were measured. Insulin resistance was assessed using the homeostasis model assessment (HOMA-IR). In order to determine a lipocalin value indicating insulin resistance, receiver operating characteristic (ROC) curves were established. Results: Serum lipocalin was significantly higher in PCOS subjects (54.26 +/- 15.58 vs 26.09 +/- 7.47 ng/ml, p=0.0001). We found a close correlation between lipocalin and insulin, lipocalin and HOMA-IR, lipocalin and T, and lipocalin and DHEAS. A cut-off level of >39.54 ng/ml for serum lipocalin has a predictive value for insulin resistance of 81% sensitivity and 82.1% specificity. Conclusion: In our study, lipocalin-2 levels were found to be significantly higher in women with PCOS compared to body mass index-matched controls. Serum lipocalin-2 may prove to be a useful marker for insulin resistance in patients with PCOS. (J. Endocrinol. Invest. 34: 97-100, 2011) (C)2011, Editrice Kurtisen_US
dc.identifier.doi10.1007/BF03347037
dc.identifier.endpage100en_US
dc.identifier.issn0391-4097
dc.identifier.issn1720-8386
dc.identifier.issue2en_US
dc.identifier.pmid20511727en_US
dc.identifier.scopus2-s2.0-79956373807en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage97en_US
dc.identifier.urihttps://doi.org/10.1007/BF03347037
dc.identifier.urihttps://hdl.handle.net/11616/95332
dc.identifier.volume34en_US
dc.identifier.wosWOS:000290372800003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Endocrinological Investigationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPolycystic ovary syndromeen_US
dc.subjectlipocalin-2en_US
dc.subjectinsulin resistanceen_US
dc.titleSerum lipocalin-2 as an insulin resistance marker in patients with polycystic ovary syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu